Nipro Corp (8086) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Nipro Corp (Nipro) develops, manufactures, and distributes medical devices, pharmaceuticals, and pharmaceutical packaging. The company’s products include renal products, interventional and anaesthesiology products, injection and infusion products, cardiopulmonary products, double bags, pre-filled syringes, and half-type kits among others. It offers contract manufacturing services of development, manufacturing of drug formulations, inspection, packaging, logistics and distribution services. Nipro also provides glass molding vials, ampoules, syringes, and cartridges; glass tubes for pharmaceuticals; glass-forming machinery; other parts of pharmaceutical packaging including rubber plugs; and glass bulbs for vacuum flasks. The company has sales offices in North America, South America, Europe, Asia and Africa. Nipro is headquartered in Settsu, Osaka, Japan.Nipro Corp Key Recent Developments
- Jul 18, 2024: Nipro to build $398m medical device facility in North Carolina, US
- Feb 21, 2023: Prevas UX/UI-expertise helps Nipro
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Taiho Pharmaceutical Co Ltd
- Fresenius SE & Co KGaA
- Mitsubishi Tanabe Pharma Corp
- Kyowa Kirin Co Ltd
- IMI Co Ltd
- Chugai Pharmaceutical Co Ltd
- Asahi Kasei Medical Co Ltd
- Terumo Corp
- JMDC Inc
- Getinge Holding BV & Co KG